Conexiant’s news site is now MDSpire News. Learn more
Advertisement
PRP May Offer the Strongest Hair Transplant Evidence
Structured review highlights stronger evidence for platelet-rich plasma than for exosome-based and other emerging regenerative therapies while underscoring the need for standardized transplantation-specific research.
To evaluate the effectiveness of regenerative therapies for hair loss and hair transplantation, focusing on platelet-rich plasma (PRP) and other emerging approaches.
Approach:
Study Design: Structured narrative review of English-language studies from PubMed/MEDLINE, Scopus, and Google Scholar through February 2025.
Eligibility Criteria: Included randomized controlled trials, prospective and retrospective clinical studies, systematic reviews, meta-analyses, and translational preclinical studies.
Outcome Measures: Assessed hair density, hair shaft diameter, graft survival, hair yield, wound healing, time to visible regrowth, shock loss, and patient-reported satisfaction.
Key Findings:
PRP had the most mature evidence base among reviewed therapies.
Randomized trials reported increases in hair density of approximately 10 to 30 hairs/cm² with PRP.
Evidence specific to hair transplantation was limited and inconsistent.
Exosome-based therapies had considerably less developed evidence, with no robust randomized trials.
Low-level laser therapy showed moderate evidence for androgenetic alopecia, but transplantation-specific data was limited.
Interpretation:
PRP is currently the best-supported regenerative adjunct in hair transplantation, but higher-quality studies are needed for broader clinical application.
Limitations:
Narrative design limited quantitative synthesis.
Potential selection bias and heterogeneity in included literature.
Variability in treatment protocols and outcome reporting.
Conclusion:
Standardized protocols and transplantation-specific outcome measures are essential for improving future evidence quality.
These 10 states have paid family or medical leave programs and health, wellness, peer support, or monitoring resources available to physicians or other health professionals.
Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.